03933.HK
The United Laboratories International Holdings Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 8.36
−0.65%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 25.9B | 13.2B | 13.8B | 13.7B | 11.3B |
| Cost of Revenue | 15.5B | 7.7B | 7.7B | 7.4B | 6.4B |
| Gross Profit | 10.3B | 5.5B | 6.1B | 6.3B | 5.0B |
| Operating Expenses | |||||
| R&D Expense | 1.4B | 921.0M | 890.8M | 757.2M | 593.6M |
| SG&A Expense | 4.7B | 2.3B | 2.3B | 2.4B | 2.4B |
| General & Admin Expense | 1.5B | 947.5M | 894.1M | 789.9M | 703.4M |
| Selling & Marketing Expense | 2.1B | 1.4B | 1.4B | 1.6B | 1.7B |
| Other Expenses | 432.9M | 18.7M | 39.3M | (95.4M) | (8.0M) |
| Total Operating Expenses | 6.5B | 3.2B | 3.2B | 3.0B | 3.0B |
| Cost and Expenses | 22.0B | 10.9B | 10.6B | 10.5B | 9.3B |
| Operating Income (EBIT) | 3.9B | 2.3B | 3.1B | 3.3B | 2.0B |
| Non-Operating | |||||
| Interest Income | 276.2M | 152.6M | 127.8M | 105.4M | 70.7M |
| Interest Expense | 93.1M | 69.7M | 35.0M | 66.9M | 81.6M |
| Net Interest Income | 183.1M | 82.8M | 92.8M | 38.5M | (10.9M) |
| Other Non-Op Income/Expense | 498.1M | 256.2M | 172.6M | 54.8M | (18.3M) |
| Non-Operating Income (excl Interest) | 4.0M | 50.2M | 303.0M | (121.7M) | 10.0M |
| EBT (Pre-Tax Income) | 4.4B | 2.5B | 3.3B | 3.3B | 2.0B |
| Income Tax Expense | 786.5M | 446.9M | 631.1M | 643.3M | 425.7M |
| Bottom Line | |||||
| Net Income | 3.6B | 2.1B | 2.7B | 2.7B | 1.6B |
| Earnings from Cont. Ops | 3.6B | 2.1B | 2.7B | 2.7B | 1.6B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 3.6B | 2.1B | 2.7B | 2.7B | 1.6B |
| Per Share | |||||
| Basic EPS | HK$1.96 | HK$1.11 | HK$1.46 | HK$1.49 | HK$0.87 |
| Diluted EPS | HK$1.96 | HK$1.11 | HK$1.46 | HK$1.49 | HK$0.87 |
| Revenue Per Share | HK$13.12 | HK$7.01 | HK$7.57 | HK$7.56 | HK$6.23 |
| Shares | |||||
| Basic Shares Outstanding | 2.0B | 1.9B | 1.8B | 1.8B | 1.8B |
| Diluted Shares Outstanding | 2.0B | 1.9B | 1.8B | 1.8B | 1.8B |
| Profitability Metrics | |||||
| EBITDA | 5.1B | 2.8B | 3.4B | 4.0B | 2.5B |
| D&A | 1.3B | 613.2M | 538.0M | 565.6M | 523.7M |
| EBIT | 3.9B | 2.2B | 2.8B | 3.4B | 2.0B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026